Pathology EMQ template.

Name: Chiraush Patel

Candidate number:

Theme: Obesity and cardiovascular risk update

OPTION LIST

A	Conjugated linoleic acid	I	Obestatin elixir
B	Diethylproprion	J	Orlistat
C	Gliclazide	K	Rimonabant
D	Green tree extract	L	Rosiglitazone
E	Hoodia	M	Roux-en-y
F	Insulin	N	Synephrine
G	Lachulose	O	Sibutramine
H	Metformin	P	Troglitazone

For each scenario below, choose the most appropriate answer from the list above. Each option may be used once, more than once or not at all.

1. This licensed anti diabetic drug activates PPAR gamma to achieve its effects

2. Cb1 receptor antagonist, approved for anti obesity use in the European Union.

3. A licensed appetite suppressant acting primarily on serotonin pathways in the brain

4. Side effects of this anti obesity drug include diarrhoea and flatulence.

5. Believed to completely ameliorate the symptoms of diabetes mellitus type 2

ANSWERS

1. L

2. K

3. O

4. J

5. M